BiopharmaceuticalsBiopharmaceuticals

News

Atrium Innovations Inc. Receives Final Court Approval of Arrangement with the Permira Funds

News - Atrium Innovations announces that the Superior Court of Québec issued a final order approving the previously announced plan of arrangement providing for the acquisition of all of the outstanding common shares of Atrium for cash consideration of $24.00 per common share by corporations backed by the Permira funds and the acquisition by the Corporation of all of its outstanding convertible debentures.

Aeterna Zentaris Announces Closing of US$13.2 Million Public Offering of Common Shares and Warrants

News - Aeterna Zentaris announces the closing of its previously announced public offering of 11.0 million units generating net proceeds of approximately US$12.2 million, with each unit consisting of one common share and 0.8 of a warrant to purchase one common share, at a purchase price of US$1.20 per unit. Each warrant is exercisable for a period of five years at an exercise price of US$1.25 per share. Canaccord Genuity Inc. acted as the sole book-running manager, and Maxim Group LLC, H. C. Wainwright & Co., LLC and MLV & Co LLC acted as co-managers for the Offering.

Université Laval and Roche team up to test promising compounds for several disorders of the brain, including autism spectrum disorders

News - Thanks to this joint initiative, Université Laval researcher Yves De Koninck and his team will be able to pursue the development of the many scientific discoveries and advances they have made in the last 10 years. Dr. De Koninck is a Professor in Université Laval’s Faculty of Medicine, Scientific Director of the Institut Universitaire en Santé Mentale de Québec, and an internationally renowned expert in the fields of neurology and neurophotonics.

Aeterna Zentaris Appoints Dr. Richard Sachse as Chief Scientific Officer

News - Aeterna Zentaris announced the appointment of Richard Sachse, MD, PhD, as Senior Vice President, Chief Scientific Officer. Before joining Aeterna Zentaris, Dr. Sachse was Vice President, Head of Global Translational Medicine at Boehringer Ingelheim.

Aeterna Zentaris NDA for Macimorelin Acetate in AGHD Accepted for Filing by the FDA

News - Aeterna Zentaris today announced that the U.S. Food and Drug Administration has accepted for filing the Company's New Drug Application for its ghrelin agonist, macimorelin acetate, in Adult Growth Hormone Deficiency. The acceptance for filing of the NDA indicates the FDA has determined that the application is sufficiently complete to permit a substantive review.

CHU de Québec seeks solutions!

Press releases - The Quebec City University Hospital Centre (CHU de Québec) is proud to be associated with Quebec Seeks Solutions (QSS) – Healthcare Edition, which is being held today. This original event, organized by Quebec International, brings together entrepreneurs, researchers and innovation enthusiasts seeking to promote ideas in response to three challenges that CHU de Québec is currently facing.

Quebec International partners with BioWin to offer a training program specifically geared towards life science entrepreneurs

Press releases - Quebec International is pleased to announce that it has reached an agreement in principle with BioWin, the healthcare competitiveness cluster based in Wallonia, Belgium. The agreement covers licensing rights under BioWin’s BioPharE program. For BioWin, this is the first time that rights have been licensed under this high-level program. As part of its role in the partnership, the Continuing Education Department at Sainte-Foy CEGEP will administer training activities during the implementation of the program, which is specifically geared towards life science entrepreneurs.

Atrium Innovations Inc. to be acquired by the Permira funds and a group of Québec investors

News - Atrium Innovations announces that it has entered into a definitive arrangement agreement with a company backed by the Permira funds whereby the Permira funds will acquire all the issued and outstanding common shares of Atrium, other than the shares to be rolled over by Fonds de solidarité FTQ and Caisse de dépôt et placement du Québec, for $24.00 in cash per Share. Upon completion of the transaction, Atrium will be jointly owned by the Permira funds (75%), the Fonds (12.5%) and CDPQ (12.5%), before management equity programs.

U.S. FDA approves Quebec-made bird flu vaccine for stockpile use only

News - The U.S. government has for the first time approved an adjuvanted vaccine to protect against H5N1 bird flu. The vaccine was made by Quebec City-based ID Biomedical, a subsidiary of pharmaceutical giant GlaxoSmithKline. The approval was announced by the Food and Drug Administration, which regulates vaccines in the United States. The vaccine will not be available commercially; it will be placed in the U.S. government’s emergency stockpile.

A Filmmaker on Migraines: 'I Could Hear the Light Bulb'

News - Filmmaker Anne De Lean has had migraines since she was a little girl. Her father, Jacques De Lean, MD, a neurologist in Quebec City, also suffers from the sometimes debilitating condition that affects 10 percent of all adults ages 18 to 65 worldwide.

Contacts

Jean-MichelGarroLife Sciences

More details

Newsletter

Subscribe to our newsletter for interesting news and information.

Print this page